5 Stocks Pushing The Health Services Industry Higher
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our modelAll three major indices are trading down today with the Dow Jones Industrial Average (^DJI) trading down 23 points (-0.2%) at 13,146 as of Friday, Dec. 14, 2012, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,344 issues advancing vs. 1,517 declining with 152 unchanged.The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.3%. Top gainers within the industry include Community Health Systems (CYH), up 1.6%, ResMed (RMD), up 1.0% and Quest Diagnostics (DGX), up 0.8%. On the negative front, top decliners within the industry include Centene Corporation (CNC), down 8.5%, WellCare Health Plans (WCG), down 5.9%, Molina Healthcare (MOH), down 4.3% and Life Technologies (LIFE), down 1.4%.TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:5. Boston Scientific (BSX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Boston Scientific is up $0.04 (0.7%) to $5.67 on light volume Thus far, 2.7 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 14.0 million shares. The stock has ranged in price between $5.66-$5.76 after having opened the day at $5.72 as compared to the previous trading day's close of $5.63. Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $7.8 billion and is part of the health care sector. Shares are up 6.2% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Boston Scientific a buy, 1 analyst rates it a sell, and 14 rate it a hold.TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Boston Scientific Ratings Report now.EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Latest Headlines about EW
-
Stocks Gain as Traders Shrug at Possible Fed Pullback
05:21PM 05/14/13
-
Short Interest In Edwards Lifesciences Decreases By 10.8%
04:30PM 05/10/13
-
Check Out The First Quarter Earnings Winner's Circle
06:52PM 04/26/13
-
Stocks Mixed as P&G Forecast Offsets Yum, Boeing
06:06PM 04/24/13
-
Cramer's 6 Stocks in 60 Seconds: JNPR EW HSY PNRA RLGY LLY (Update 1)
05:16PM 04/24/13
-
'Mad Money' Lightning Round: I'm Avoiding Controversial Coinstar
06:00AM 02/07/13
-
Cramer's 'Mad Money' Recap: Pay Attention
07:53PM 02/06/13
Latest from TheStreet Wire
-
Randgold Resources Ltd (GOLD): Today's Featured Basic Materials Laggard
05:01PM 06/18/13
-
Pinnacle West Capital Corporation (PNW): Today's Featured Utilities Laggard
05:01PM 06/18/13
-
Saks Incorporated (SKS): Today's Featured Retail Laggard
05:01PM 06/18/13
-
Catamaran Corp (CTRX): Today's Featured Computer Software & Services Laggard
05:01PM 06/18/13
-
Leucadia National Corporation (LUK): Today's Featured Food & Beverage Laggard
05:01PM 06/18/13
-
Clearwire Corp (CLWR): Today's Featured Telecommunications Laggard
05:01PM 06/18/13
-
Infosys Ltd (INFY): Today's Featured Technology Laggard
05:01PM 06/18/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
